12/10/2013

California-based pharmaceutical company MannKind is seeking government approval for a new form of insulin powder that can be inhaled instead of injected to treat both type 1 and type 2 diabetes. The drug, called Afrezza, has completed Phase III trials and is now under FDA review.

Related Summaries